Center expected to increase regional COVID antibody infusions by 500%

Beaumont Enterprise – AshBritt IEM Health set up the infusion center, as it has done with many others across the country, said Global Medical Director Dr. Rashid Chotani. “All the infusion centers that we put together have demonstrated clearly that getting the drug decreases the intensity of the disease,” Chotani said. “Regeneron and monoclonal antibodies were developed last year at the same time as the vaccines were being developed. The FDA, the CDC and the government have said that Regeneron is the best choice of monoclonal antibodies that we have at this time.”